Objetivo del estudio: This is a Phase 1 trial to investigate the safety and efficacy of the investigational drug, DCC-2618, administered orally (PO), in adult patients with advanced malignancies.
Patrocinador: Deciphera Pharmaceuticals LLC
Datos de contacto del ensayo: Divya Sakamuri; 1-713-745-3296; dsakamuri@mdanderson.org or Filip Janku; 713-563-1930; FJanku@mdanderson.org
Participación solicitada del paciente: ECD patients 18 years or older.
Centros conocidos que admiten a pacientes con ECD en el ensayo: MD Anderson, Houston, Texas
Identificador de ClinicalTrials.gov: NCT02571036

